2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylacetamide | 151290-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylacetamide
• CAS: 151290-19-6
• 化学式: C₁₃H₁₆N₂O₂
• 分子量: 232.282
• InChiKey: DZJBXCDGTLDTOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  45.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylacetamide 在 lithium aluminium tetrahydride 、 氢溴酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 9.0h， 生成 蟾毒色胺
  参考文献：
  名称：

  Synthesis of 131I derivatives of indolealkylamines for brain mapping

  摘要：

  The synthesis and spectral properties of new radioiodinated indolealkylamines like 2-[I-131]-iodo-N,N-dimethyltryptamine, 2-[I-131]-iodo-N-methyltryptamine, 2-[I-131]-iodo-5-methoxy-N,N-dimethyltryptamine, 2-[I-131]-iodo-5-hydroxy-N,N-dimethyltryptamine (2-[I-131]-iodo-bufotenine), and 2-[I-131]-iodo-tryptamine and the known 2-[I-131]-iodo-N-acetyl-5-methoxy-tryptamine (2-[I-131]-iodo-melatonine) are described herein. These were synthesized by a high-yield novel method, and their spectral properties are fully described. These compounds are of biological importance and can be used for brain mapping with SPECT technology.

  DOI：

  10.1002/(sici)1099-1344(199708)39:8<677::aid-jlcr9>3.0.co;2-g
• 作为产物：
  描述：

  5-甲氧基吲哚-3-乙酸 在 硫酸 作用下， 以 水 为溶剂， 反应 42.0h， 生成 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylacetamide
  参考文献：
  名称：

  Synthesis of 131I derivatives of indolealkylamines for brain mapping

  摘要：

  The synthesis and spectral properties of new radioiodinated indolealkylamines like 2-[I-131]-iodo-N,N-dimethyltryptamine, 2-[I-131]-iodo-N-methyltryptamine, 2-[I-131]-iodo-5-methoxy-N,N-dimethyltryptamine, 2-[I-131]-iodo-5-hydroxy-N,N-dimethyltryptamine (2-[I-131]-iodo-bufotenine), and 2-[I-131]-iodo-tryptamine and the known 2-[I-131]-iodo-N-acetyl-5-methoxy-tryptamine (2-[I-131]-iodo-melatonine) are described herein. These were synthesized by a high-yield novel method, and their spectral properties are fully described. These compounds are of biological importance and can be used for brain mapping with SPECT technology.

  DOI：

  10.1002/(sici)1099-1344(199708)39:8<677::aid-jlcr9>3.0.co;2-g

文献信息

• [EN] INJECTABLE FORMULATION<br/>[FR] FORMULATION INJECTABLE
  申请人：SMALL PHARMA LTD

  公开号：WO2022043227A1

  公开（公告）日：2022-03-03

  Provided herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are optionally suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.

  本文提供了制药配方、制造方法及其用途。该制药配方包括一种可选取代的二甲基色胺盐、一个与盐分离的缓冲剂和水。该配方的pH值约为3.5至6.5，渗透压约为250至350 mOsm/Kg。这种配方可选用于注射，具有稳定性和临床可接受性，并有潜在用途于治疗精神或神经疾病。
• [EN] CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS<br/>[FR] PROCÉDÉS ET PRÉCURSEURS DE TRYPTAMINE CATALYTIQUES
  申请人：KARE CHEMICAL TECH INC

  公开号：WO2022232931A1

  公开（公告）日：2022-11-10

  The present disclosure relates to the use of tryptamine precursor compounds and zinc amide enolate compounds for the preparation of tryptamines. The disclosure also relates to the use of catalysts and catalytic processes for the preparation of tryptamines using the zinc amide enolate compounds and the tryptamine precursor compounds.

  本公开涉及使用色胺前体化合物和锌酰胺烯醇化合物制备色胺。该公开还涉及使用催化剂和催化过程，使用锌酰胺烯醇化合物和色胺前体化合物制备色胺。
• DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS
  申请人：Small Pharma Ltd

  公开号：US20220202775A1

  公开（公告）日：2022-06-30

  The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I′) is also provided.
• [EN] DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS<br/>[FR] COMPOSÉS DE N,N-DIMÉTHYLTRYPTAMINE DEUTÉRÉS OU PARTIELLEMENT DEUTÉRÉS
  申请人：[en]SMALL PHARMA LTD

  公开号：WO2022117359A1

  公开（公告）日：2022-06-09

  The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I') is also provided.
• US2023/86574
  申请人：——

  公开号：——

  公开（公告）日：——